ONPHOncology Pharma Inc.
Oct 20, 2026 — Emergency Equity Offering / Highly Dilutive Raise
Chart by TradingViewThe schedule
- Tue20Oct
Anticipated highly dilutive capital raise or debt-to-equity conversion to fund basic corporate operations and avoid insolvency.
- Tue15Dec
- Thu14Jan
Required update on clinical progress or out-licensing attempts for any remaining oncology assets to sustain public market interest.
- Tue30Mar
Full-year 2026 financial results with a high probability of a 'Going Concern' qualification from auditors.
- Sat15May
Potential reverse stock split implementation to artificially inflate the share price and avoid complete delisting from OTC/exchange tiers.
- Tue15Jun
- Tue14Sep
Past
- Tue15Sep
Estimated Q2 2026 earnings release, serving as a critical liquidity check for a company operating with extreme financial leverage and near-zero cash.